Bongers M E R, Groot O Q, Thio Q C B S, Bramer J A M, Verlaan J J, Newman E T, Raskin K A, Lozano-Calderon S A, Schwab J H
Department of Orthopaedic Surgery, Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA.
Department of Orthopaedic Surgery, Academic University Medical Center, University of Amsterdam, Amsterdam, The Netherlands.
Acta Oncol. 2021 Jun;60(6):714-720. doi: 10.1080/0284186X.2021.1890333. Epub 2021 Feb 25.
The clinical relevance of patient-reported outcomes score changes is often unclear. Especially in patients undergoing surgery due to lower extremity metastases - where surgery is performed in the palliative setting and the goal is to optimize functional mobility, relieve pain and improve overall quality of life. This study assessed the minimal clinically important difference (MCID) of Patient-Reported Outcomes Measurement Information System (PROMIS) Pain Interference, Cancer-specific Physical Function, and Global (Physical and Mental Health) in patients treated surgically for impending or completed pathologic fractures.
Patients undergoing surgery for osseous metastasis of the lower extremity because of an impending or completed pathologic fracture were consecutively enrolled in this tertiary center study. Patients completed the three PROMIS questionnaires preoperatively ( = 56) and at postoperative follow-up ( = 33) assessment one to three months later. Of the 23 patients that did not complete the postoperative survey, 5 patients died within 1-3 months and 18 patients were alive at 3-months but did not respond or show up at their postoperative consult. Thirty-one patients (94%) of the 33 included patients reported at least minimal improvement and two patients (6.1%) no change 1-3 months after the surgery based on an anchor-based approach.
The PROMIS MCIDs (95% confidence interval) for Pain Interference was 7.5 (3.4-12), Physical Function 4.1 (0.6-7.6), Global Physical Health 4.2 (2.0-6.6), and Global Mental Health 0.8 (-4.5-2.9).
This prospective study successfully defined a MCID for PROMIS Pain Interference of 7.5 (3.4-12), PROMIS Physical Function of 4.1 (0.6-7.6), and Global Physical Health of 4.2 (2.0-6.6) in patients with (impending) pathological fractures due to osseous metastases in the lower extremity; no MCID could be established for PROMIS Global Mental Health. Defining a narrower MCID value for each subpopulation requires a large, prospective, multicenter study. Nevertheless, the provided MCID values allow guidance to clinicians to evaluate the impact of surgical treatment on a patient's QoL.
Level II Diagnostic study.
患者报告结局评分变化的临床相关性往往不明确。尤其是在因下肢转移瘤而接受手术的患者中——此类手术是在姑息治疗环境下进行的,目标是优化功能活动能力、缓解疼痛并改善总体生活质量。本研究评估了患者报告结局测量信息系统(PROMIS)疼痛干扰、癌症特异性身体功能以及整体(身体和心理健康)在因即将发生或已发生的病理性骨折而接受手术治疗的患者中的最小临床重要差异(MCID)。
因即将发生或已发生的病理性骨折而接受下肢骨转移瘤手术的患者连续纳入本三级中心研究。患者在术前(n = 56)以及术后1至3个月的随访评估时(n = 33)完成了三份PROMIS问卷。在未完成术后调查的23例患者中,5例在1至3个月内死亡,18例在3个月时存活,但未回复或未出现在术后咨询中。基于锚定法,纳入研究的33例患者中有31例(94%)报告至少有最小程度的改善,2例(6.1%)在术后1至3个月无变化。
PROMIS疼痛干扰的MCID(95%置信区间)为7.5(3.4 - 12),身体功能为4.1(0.6 - 7.6),整体身体健康为4.2(2.0 - 6.6),整体心理健康为0.8(-4.5 - 2.9)。
这项前瞻性研究成功确定了因下肢骨转移瘤导致(即将发生)病理性骨折的患者中,PROMIS疼痛干扰的MCID为7.5(3.4 - 12),PROMIS身体功能为4.1(0.6 - 7.6),整体身体健康为4.2(2.0 - 6.6);无法确定PROMIS整体心理健康的MCID。为每个亚组定义更窄的MCID值需要一项大型、前瞻性、多中心研究。尽管如此,所提供的MCID值可为临床医生评估手术治疗对患者生活质量的影响提供指导。
二级诊断性研究。